<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758392</url>
  </required_header>
  <id_info>
    <org_study_id>CR108162</org_study_id>
    <secondary_id>61178104NAP1001</secondary_id>
    <secondary_id>2015-004253-40</secondary_id>
    <nct_id>NCT02758392</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Interventional Study of JNJ-61178104 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and&#xD;
      immunogenicity of JNJ-61178104 following a single ascending Intravenous (IV) dose&#xD;
      administration and a single Subcutaneous (SC) dose administration in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending dose, single site,&#xD;
      interventional study. There will be 5 single ascending dose (SAD) IV cohorts and 1 SC cohort.&#xD;
      Nine participants will be enrolled into each of 5 IV cohorts and 1 SC cohort and participants&#xD;
      will be randomized at a ratio of 2:1 to receive JNJ-61178104 or placebo. The total duration&#xD;
      of participants participation will be approximately 21 weeks including a Screening Visit up&#xD;
      to 4 weeks prior to study drug administration. Participants will have an inpatient period&#xD;
      consisting of 6 days/5 nights and will return to the study-site at Weeks 2, 3, 4, 5, 7, 9,&#xD;
      13, and 17. Participants will be evaluated for safety throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events Following Study Drug Administration as a Measure of Safety and Tolerability</measure>
    <time_frame>Day 113</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of JNJ-61178104</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JNJ-61178104 Antibodies Concentration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine Concentrations</measure>
    <time_frame>Predose, Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time Zero to Time 't' (AUC[0-t]) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Serum Concentration-Time Curve From Time Zero to Infinite Time (AUC[0-infinity]) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Half-Life (t1/2) Following Intravenous (IV) and Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Serum Concentration (Tmax) Following Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) Following Intravenous (IV) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F) Following Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vz) Following Intravenous (IV) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F) Following Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Bioavailability (F[abs]) Following Subcutaneous (SC) JNJ-61178104 Administration</measure>
    <time_frame>Up to Day 113</time_frame>
    <description>The F is the percentage of the subcutaneously administered dose that is systemically available relative to an intravenous (IV) administration. It is calculated as (AUC [0-infinity] for 1 mg/kg SC JNJ-61178104)/(AUC [0-infinity] for 1 mg/kg IV JNJ-61178104 )*100, where the AUC (0-infinity) is area under the concentration-time curve from time zero to extrapolated infinite time.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Dose 1: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-61178104 0.1 milligram/kilogram (mg/kg) or Placebo Intravenously (IV) on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-61178104 0.3 mg/kg or Placebo IV on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-61178104 1 mg/kg or Placebo IV on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-61178104 3 mg/kg or Placebo IV on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-61178104 10 mg/kg or Placebo IV on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6: JNJ-61178104 OR Placebo SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive either JNJ-61178104 1 mg/kg or Placebo Subcutaneously (SC) on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-61178104 Intravenous</intervention_name>
    <description>Participants will receive JNJ-61178104 Intravenously on Day 1.</description>
    <arm_group_label>Dose 1: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 2: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 3: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 4: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 5: JNJ-61178104 OR Placebo IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-61178104 Subcutaneous</intervention_name>
    <description>Participants will receive JNJ-61178104 Subcutaneously on Day 1.</description>
    <arm_group_label>Dose 6: JNJ-61178104 OR Placebo SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo on Day 1.</description>
    <arm_group_label>Dose 1: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 2: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 3: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 4: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 5: JNJ-61178104 OR Placebo IV</arm_group_label>
    <arm_group_label>Dose 6: JNJ-61178104 OR Placebo SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Participant must sign an informed consent form (ICF) indicating that he or she&#xD;
             understands the purpose of and procedures required for the study and are willing to&#xD;
             participate in the study&#xD;
&#xD;
          -  Participant must have a body weight in the range of 50 Kilogram (kg) to 100 kg,&#xD;
             inclusive, and have a body mass index of 19 Kilogram per meter square (kg/m^2) to 30&#xD;
             kg/m2, inclusive&#xD;
&#xD;
          -  Participant must be healthy on the basis of clinical laboratory tests performed at&#xD;
             Screening and Day-1. If the results of the serum chemistry panel including liver&#xD;
             enzymes, hematology panel, or urinalysis are outside the normal reference ranges, the&#xD;
             participant may be included only if the investigator judges the abnormalities or&#xD;
             deviations from normal to be not clinically significant or to be appropriate and&#xD;
             reasonable for the population under study. This determination must be recorded in the&#xD;
             participant's medical record with documented review confirmation by the investigator&#xD;
&#xD;
          -  Before randomization, a woman must not be of childbearing potential: a) Postmenopausal&#xD;
             {greater than (&gt;) 45 years of age with amenorrhea for at least 12 months or any age&#xD;
             with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH)&#xD;
             level &gt;40 International Units Per Litre (IU/L) at Screening}; or b) Permanently&#xD;
             sterilized (example, bilateral tubal occlusion, hysterectomy, bilateral salpingectomy,&#xD;
             oophorectomy); or c) Otherwise be incapable of pregnancy&#xD;
&#xD;
          -  Be considered eligible according to the following tuberculosis (TB) Screening&#xD;
             criteria: a) Have no history of latent or active TB prior to Screening; b) Have no&#xD;
             signs or symptoms suggestive of active TB upon medical history and/or physical&#xD;
             examination; c) Have had no recent close contact with a person with active TB; d) Have&#xD;
             a negative T-Spot TB test result at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant currently has or has a history of any clinically significant medical&#xD;
             illness or medical disorders the investigator considers should exclude the&#xD;
             participant, including (but not limited to), neuromuscular, hematological disease,&#xD;
             immune deficiency state, cardiac, vascular, metabolic, endocrine, rheumatologic,&#xD;
             respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric&#xD;
             disease, ophthalmological disorders, neoplastic disease, renal or urinary tract&#xD;
             diseases, or dermatological disease&#xD;
&#xD;
          -  Participant has a QT corrected according to Fridericia's formula (QTcF) interval &gt;450&#xD;
             msec, has a complete left or right bundle branch block, or has a history or current&#xD;
             evidence of additional risk factors for torsades de pointes (example, heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome) at Screening and at Day -1&#xD;
&#xD;
          -  Participant has had major surgery, (example, requiring general anesthesia) within 4&#xD;
             months before Screening, or will not have fully recovered from surgery, or has surgery&#xD;
             planned during the time the participant is expected to participate in the study or&#xD;
             within 17 weeks after the last dose of study drug administration&#xD;
&#xD;
          -  Participant plans to undergo non-major elective surgery within 4 weeks prior to study&#xD;
             drug administration through the end of the study&#xD;
&#xD;
          -  Participant has a known or suspected intolerance or hypersensitivity to any biologic&#xD;
             medication or known allergies or clinically significant reactions to murine, chimeric,&#xD;
             or human proteins, monoclonal antibodies or antibody fragments, or to any components&#xD;
             of the formulation of JNJ-61178104 and its excipients used in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Merksem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>January 20, 2017</last_update_submitted>
  <last_update_submitted_qc>January 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <keyword>JNJ-61178104</keyword>
  <keyword>Placebo</keyword>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

